Foreign Generics See Ripe Market In Price Conscious Japan
This article was originally published in PharmAsia News
Executive Summary
Generic makers in other countries are setting their sights on Japan as the place for major expansions. Israel's Teva Pharmaceutical Industries and India's Ranbaxy Laboratories are among companies that plan to take advantage of the Japanese government's initiative to reduce the price of prescriptions. Ranbaxy has been trying to gain ground in Japan's market since it teamed with Nippon Chemiphar six years ago, but now it hopes to gain ground with its amlodipine generic of Pfizer's blockbuster Norvasc blood pressure drug. Other foreign generics planning expansions include Sandoz of Germany and Zydus Cadila of India. (Click here for more - a subscription may be required